Status:
RECRUITING
U-LABA/ICS Effects on Exercise Performance, Indacaterol
Lead Sponsor:
Morten Hostrup, PhD
Conditions:
Exercise Performance
Eligibility:
All Genders
18-39 years
Phase:
NA
Brief Summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Eligibility Criteria
Inclusion
- Age 18-39
- Physically active \> 5 h weekly
- Maximal oxygen consumption classified as high or very high
Exclusion
- Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- ECG abnormality
- ACQ score \> 1.5
- Severe bronchial hyperreactivity as determined by mannitol test
- FEV1/FVC ratio \< 0.7 determined with spirometry
- Chronic illness determined to be a potential risk for participant during study
- In chronic treatment with medication that may interfere with study results
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Key Trial Info
Start Date :
January 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06067100
Start Date
January 15 2024
End Date
December 1 2026
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
August Krogh Building
Copenhagen, Denmark, 2100